FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563565179> ?p ?o ?g. }

• W2563565179 endingPage "28" @default.
• W2563565179 startingPage "15" @default.
• W2563565179 abstract "A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization Navya Sree Kola Srinivas,1 Ruchi Verma,2 Girish Pai Kulyadi,1 Lalit Kumar1 1Department of Pharmaceutics, 2Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India Abstract: Gefitinib is an anticancer agent which acts by inhibiting epidermal growth factor receptor tyrosine kinase receptors. The aim of the present study was to prepare gefitinib nanosuspension. Gefitinib was encapsulated in Eudragit® RL100 and then dispersed in stabilizer solution, polyvinyl alcohol, and polyvinylpyrrolidone K30. Nanosuspension was prepared by using homogenization and ultrasonication techniques. The quality by design approach was also used in the study to understand the effect of critical material attributes (CMAs) and critical processing parameters (CPPs) on critical quality attributes and to improve the quality and safety of formulation. To study the effect of CMAs and CPPs, 23 full factorial design was applied. The particle size, polydispersity index, and zeta potential of the optimized solution were 248.20 nm, 0.391, and -5.62 mV, respectively. Drug content of the optimized nanoformulation was found to be 87.74%±1.19%. Atomic force microscopy studies of the optimized formulation confirmed that the prepared nanoparticles are smooth and spherical in nature. In vitro cytotoxicity studies of the nanosuspension on Vero cell line revealed that the formulation is nontoxic. The gefitinib nanosuspension released 60.03%±4.09% drug over a period of 84 h, whereas standard drug dispersion released only 10.39%±3.37% drug in the same duration. From the pharmacokinetic studies, half-life, Cmax, and Tmax of the drug of an optimized nanosuspension were found to be 8.65±1.99 h, 46,211.04±5,805.97 ng/mL, and 6.67±1.77 h, respectively. A 1.812-fold increase in relative bioavailability of nanosuspension was found, which confirmed that the present formulation is suitable to enhance the oral bioavailability of gefitinib. Keywords: gefitinib, cancer, epidermal growth factor receptor tyrosine kinase receptors inhibitor, bioavailability, Eudragit® RL100, PVP K30, PVA, Biopharmaceutical Classification System class II, QbD, design of experiment, full factorial design" @default.
• W2563565179 created "2017-01-06" @default.
• W2563565179 creator A5003214240 @default.
• W2563565179 creator A5007621555 @default.
• W2563565179 creator A5036896629 @default.
• W2563565179 creator A5062708090 @default.
• W2563565179 date "2016-12-01" @default.
• W2563565179 modified "2023-10-17" @default.
• W2563565179 title "A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization" @default.
• W2563565179 cites W1197948068 @default.
• W2563565179 cites W1629179716 @default.
• W2563565179 cites W1664986234 @default.
• W2563565179 cites W1801854103 @default.
• W2563565179 cites W1973151270 @default.
• W2563565179 cites W1974903851 @default.
• W2563565179 cites W1977717521 @default.
• W2563565179 cites W1981468523 @default.
• W2563565179 cites W1982982125 @default.
• W2563565179 cites W1987390912 @default.
• W2563565179 cites W1995015657 @default.
• W2563565179 cites W1998154903 @default.
• W2563565179 cites W2010908849 @default.
• W2563565179 cites W2012100899 @default.
• W2563565179 cites W2013081613 @default.
• W2563565179 cites W2015407801 @default.
• W2563565179 cites W2018504340 @default.
• W2563565179 cites W2021639519 @default.
• W2563565179 cites W2032439697 @default.
• W2563565179 cites W2038245122 @default.
• W2563565179 cites W2047905490 @default.
• W2563565179 cites W2059968522 @default.
• W2563565179 cites W2065479189 @default.
• W2563565179 cites W2067648153 @default.
• W2563565179 cites W2067763594 @default.
• W2563565179 cites W2068983836 @default.
• W2563565179 cites W2069295596 @default.
• W2563565179 cites W2069444430 @default.
• W2563565179 cites W2083571917 @default.
• W2563565179 cites W2084632517 @default.
• W2563565179 cites W2094864238 @default.
• W2563565179 cites W2094968130 @default.
• W2563565179 cites W2103302691 @default.
• W2563565179 cites W2106268433 @default.
• W2563565179 cites W2110167132 @default.
• W2563565179 cites W2111527111 @default.
• W2563565179 cites W2114918609 @default.
• W2563565179 cites W2116395976 @default.
• W2563565179 cites W2120060289 @default.
• W2563565179 cites W2122185071 @default.
• W2563565179 cites W2133667721 @default.
• W2563565179 cites W2139637498 @default.
• W2563565179 cites W2141885213 @default.
• W2563565179 cites W2143555751 @default.
• W2563565179 cites W2156504855 @default.
• W2563565179 cites W2266575795 @default.
• W2563565179 cites W2297311793 @default.
• W2563565179 cites W2325867002 @default.
• W2563565179 cites W789663051 @default.
• W2563565179 doi "https://doi.org/10.2147/ijn.s122729" @default.
• W2563565179 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5179202" @default.
• W2563565179 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28031710" @default.
• W2563565179 hasPublicationYear "2016" @default.
• W2563565179 type Work @default.
• W2563565179 sameAs 2563565179 @default.
• W2563565179 citedByCount "63" @default.
• W2563565179 countsByYear W25635651792017 @default.
• W2563565179 countsByYear W25635651792018 @default.
• W2563565179 countsByYear W25635651792019 @default.
• W2563565179 countsByYear W25635651792020 @default.
• W2563565179 countsByYear W25635651792021 @default.
• W2563565179 countsByYear W25635651792022 @default.
• W2563565179 countsByYear W25635651792023 @default.
• W2563565179 crossrefType "journal-article" @default.
• W2563565179 hasAuthorship W2563565179A5003214240 @default.
• W2563565179 hasAuthorship W2563565179A5007621555 @default.
• W2563565179 hasAuthorship W2563565179A5036896629 @default.
• W2563565179 hasAuthorship W2563565179A5062708090 @default.
• W2563565179 hasBestOaLocation W25635651791 @default.
• W2563565179 hasConcept C105795698 @default.
• W2563565179 hasConcept C11432220 @default.
• W2563565179 hasConcept C150903083 @default.
• W2563565179 hasConcept C155672457 @default.
• W2563565179 hasConcept C169222746 @default.
• W2563565179 hasConcept C170493617 @default.
• W2563565179 hasConcept C171250308 @default.
• W2563565179 hasConcept C181389837 @default.
• W2563565179 hasConcept C18150654 @default.
• W2563565179 hasConcept C185592680 @default.
• W2563565179 hasConcept C188027245 @default.
• W2563565179 hasConcept C192562407 @default.
• W2563565179 hasConcept C207001950 @default.
• W2563565179 hasConcept C2779438470 @default.
• W2563565179 hasConcept C2779820397 @default.
• W2563565179 hasConcept C2780580887 @default.
• W2563565179 hasConcept C33923547 @default.
• W2563565179 hasConcept C55493867 @default.
• W2563565179 hasConcept C71924100 @default.
• W2563565179 hasConcept C86181022 @default.

• next